Your browser is no longer supported. Please, upgrade your browser.
Settings
BMY [NYSE]
Bristol-Myers Squibb Company
IndexS&P 500 P/E- EPS (ttm)-4.02 Insider Own0.10% Shs Outstand2.25B Perf Week1.77%
Market Cap140.10B Forward P/E7.73 EPS next Y8.04 Insider Trans-5.52% Shs Float2.22B Perf Month-3.63%
Income-9015.00M PEG- EPS next Q1.84 Inst Own76.40% Short Float0.94% Perf Quarter0.29%
Sales42.52B P/S3.30 EPS this Y-298.80% Inst Trans0.04% Short Ratio1.78 Perf Half Y-0.97%
Book/sh16.79 P/B3.70 EPS next Y7.33% ROA-7.20% Target Price75.13 Perf Year0.10%
Cash/sh7.02 P/C8.85 EPS next 5Y21.35% ROE-19.30% 52W Range45.76 - 67.16 Perf YTD0.11%
Dividend1.96 P/FCF15.19 EPS past 5Y-44.40% ROI-12.10% 52W High-7.53% Beta0.61
Dividend %3.16% Quick Ratio1.50 Sales past 5Y20.80% Gross Margin73.80% 52W Low35.71% ATR1.37
Employees30250 Current Ratio1.60 Sales Q/Q39.30% Oper. Margin-20.30% RSI (14)52.92 Volatility2.40% 2.16%
OptionableYes Debt/Eq1.34 EPS Q/Q-708.70% Profit Margin-21.20% Rel Volume1.46 Prev Close62.59
ShortableYes LT Debt/Eq1.28 EarningsFeb 04 BMO Payout- Avg Volume11.69M Price62.10
Recom1.90 SMA201.70% SMA50-0.25% SMA2001.88% Volume17,008,558 Change-0.78%
Nov-16-20Upgrade Societe Generale Hold → Buy $76
Nov-10-20Resumed Bernstein Mkt Perform
Nov-06-20Downgrade Gabelli & Co Buy → Hold
Oct-19-20Upgrade Guggenheim Neutral → Buy $70
Sep-29-20Initiated Berenberg Buy $73
Jul-28-20Initiated Raymond James Outperform $75
Apr-02-20Upgrade Morgan Stanley Equal-Weight → Overweight $64
Mar-23-20Downgrade Societe Generale Buy → Hold $50
Feb-27-20Initiated Barclays Equal Weight $69
Jan-06-20Resumed Citigroup Buy $73
Dec-13-19Upgrade Argus Hold → Buy $80
Nov-22-19Resumed Morgan Stanley Equal-Weight $60
Oct-17-19Resumed BofA/Merrill Buy $60
Aug-14-19Upgrade Atlantic Equities Neutral → Overweight $63
May-28-19Initiated Goldman Buy
May-20-19Downgrade Argus Buy → Hold
May-03-19Upgrade Barclays Equal Weight → Overweight $53 → $55
May-03-19Resumed JP Morgan Overweight $62
Jan-15-19Upgrade Societe Generale Sell → Buy
Oct-22-18Downgrade Citigroup Buy → Neutral
Feb-24-21 12:15PM  
09:31AM  
08:07AM  
07:10AM  
06:59AM  
Feb-23-21 09:00AM  
06:59AM  
Feb-22-21 06:15PM  
04:38PM  
Feb-20-21 12:01PM  
07:00AM  
Feb-19-21 05:04PM  
Feb-18-21 09:29PM  
Feb-17-21 04:19PM  
12:06PM  
06:54AM  
Feb-16-21 06:26PM  
12:13PM  
06:30AM  
Feb-15-21 11:00PM  
08:29PM  
06:16PM  
Feb-12-21 02:14PM  
07:00AM  
Feb-11-21 09:13AM  
09:13AM  
Feb-10-21 05:19PM  
10:49AM  
Feb-09-21 04:22PM  
11:14AM  
10:19AM  
09:22AM  
08:15AM  
Feb-08-21 07:24PM  
05:00PM  
05:00PM  
12:12PM  
11:04AM  
Feb-07-21 08:35AM  
Feb-05-21 04:39PM  
04:17PM  
06:59AM  
06:06AM  
02:01AM  
Feb-04-21 06:00PM  
05:56PM  
04:56PM  
04:38PM  
04:31PM  
04:20PM  
04:10PM  
12:47PM  
12:00PM  
11:39AM  
11:04AM  
10:11AM  
09:50AM  
08:30AM  
08:25AM  
07:45AM  
07:21AM  
07:18AM  
06:59AM  
06:59AM  
06:30AM  
03:33AM  
02:08AM  
Feb-03-21 11:42AM  
06:59AM  
06:02AM  
Feb-02-21 06:59AM  
06:59AM  
06:06AM  
05:50AM  
Feb-01-21 01:05PM  
10:46AM  
07:50AM  
06:59AM  
Jan-28-21 04:40PM  
12:32PM  
10:50AM  
Jan-25-21 05:45PM  
Jan-24-21 10:30AM  
06:45AM  
05:51AM  
Jan-22-21 01:18PM  
12:10PM  
07:50AM  
Jan-21-21 08:00AM  
06:59AM  
Jan-20-21 06:59AM  
06:59AM  
Jan-18-21 04:10PM  
Jan-15-21 05:45PM  
12:19PM  
07:15AM  
Jan-14-21 04:35PM  
02:52PM  
Jan-12-21 05:45PM  
04:56PM  
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. The company also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a solvent-free protein-bound chemotherapy product; mpliciti for the treatment of multiple myeloma; and Reblozyl for the treatment of anemia in adult patients with beta thalassemia. In addition, it offers Onureg for the continued treatment of adult patients with AML; Zeposia to treat relapsing forms of multiple sclerosis; Vidaza for the treatment of myelodysplastic syndrome subtypes; Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B; and Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. The company sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. It has collaboration agreements with Pfizer, Inc.; Otsuka Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; and Nektar Therapeutics. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
VESSEY RUPERTEVP, Research & Early Dev.Feb 04Option Exercise0.003,592058,409Feb 08 07:28 PM
Elkins David VEVP, Chief Financial OfficerDec 31Option Exercise0.0020,624079,111Jan 05 08:13 PM
VESSEY RUPERTEVP, Research & Early Dev.Dec 31Option Exercise0.0025,866068,074Jan 05 08:14 PM
AHMED NADIMEVP and President, HematologyDec 31Option Exercise0.0014,946046,549Jan 05 08:13 PM
Elkins David VEVP, Chief Financial OfficerDec 02Option Exercise0.008,792063,574Dec 03 08:24 PM
AHMED NADIMEVP and President, HematologyDec 02Option Exercise0.006,594034,983Dec 03 08:24 PM
VESSEY RUPERTEVP, Research & Early Dev.Dec 02Option Exercise0.008,792046,714Dec 03 08:24 PM
BOERNER CHRISTOPHER S.EVP, Chief Commercial OfficerDec 02Option Exercise0.002,637023,670Dec 03 08:23 PM
Eid JosephSVP,Head Glob. Medical AffairsDec 01Option Exercise0.002,82505,359Dec 03 05:15 PM
von Autenried PaulEVP, Chief Information OfficerNov 25Sale63.503191126,698Nov 30 05:52 PM
von Autenried PaulEVP, Chief Information OfficerNov 24Sale62.7520,0001,255,000126,701Nov 25 04:31 PM
Dubow AdamSVP,ChiefCompliance&EthicsOff.Nov 24Sale63.3990057,05115,186Nov 25 04:32 PM
VESSEY RUPERTEVP, Research & Early Dev.Nov 23Sale61.3413,421823,24437,922Nov 25 04:32 PM
VESSEY RUPERTEVP, Research & Early Dev.Nov 19Option Exercise49.2852,2132,572,88798,355Nov 23 05:40 PM
VESSEY RUPERTEVP, Research & Early Dev.Nov 19Sale61.3057,5913,530,26946,142Nov 23 05:40 PM
AHMED NADIMEVP and President, HematologyOct 30Option Exercise0.004,650030,680Nov 03 04:28 PM
VESSEY RUPERTEVP, Research & Early Dev.Oct 30Option Exercise0.005,804059,580Nov 03 04:27 PM
Santiago Karen MurphySVP & ControllerSep 01Option Exercise0.0064208,390Sep 02 04:33 PM
Caforio GiovanniChairman and CEOAug 31Sale62.7039,8402,497,968445,584Sep 02 04:34 PM
Eid JosephSVP,Head Glob. Medical AffairsAug 17Sale64.005,327340,9282,534Aug 19 06:15 PM
LEUNG SANDRAEVP, General CounselAug 13Sale63.24141,4208,943,401432,744Aug 17 04:55 PM
Elkins David VEVP, Chief Financial OfficerAug 01Option Exercise0.0046,402080,698Aug 04 04:43 PM
Hirawat SamitEVP,Chief Med.Offr.,Drug Dev.Jul 01Option Exercise0.009,35609,356Jul 02 04:56 PM
Santiago Karen MurphySVP & ControllerJul 01Option Exercise0.001,06908,115Jul 02 04:54 PM
Paliwal Dinesh CDirectorJun 15Buy54.509,174499,98322,109Jun 16 05:15 PM
Haller Julia ADirectorJun 14Option Exercise0.0055806,819Jun 16 05:15 PM
BONNEY MICHAEL WDirectorJun 14Option Exercise0.0055808,650Jun 16 05:16 PM
Haller Julia ADirectorJun 13Option Exercise0.0090306,261Jun 16 05:15 PM
BONNEY MICHAEL WDirectorJun 13Option Exercise0.0090308,092Jun 16 05:16 PM
Eid JosephSVP,Head Glob. Medical AffairsJun 03Option Exercise0.002,15408,599Jun 09 07:15 PM
Haller Julia ADirectorJun 03Option Exercise0.002,94905,358Jun 05 04:39 PM
BONNEY MICHAEL WDirectorJun 03Option Exercise0.002,94907,189Jun 05 04:40 PM
Dubow AdamSVP,ChiefCompliance&EthicsOff.May 22Sale61.013,200195,23216,086May 26 05:17 PM
Schmukler Louis SEVP,Pres.,Glob.Prod. & SupplyMay 19Sale62.6825,0001,567,00026,777May 21 05:22 PM
VESSEY RUPERTEVP, Research & Early Dev.May 01Option Exercise0.0010,707059,050May 05 04:49 PM
AHMED NADIMEVP and President, HematologyMay 01Option Exercise0.002,908027,463May 05 04:49 PM
Schmukler Louis SEVP,Pres.,Glob.Prod. & SupplyMar 10Option Exercise0.0030,519058,379Mar 12 06:18 PM
von Autenried PaulEVP, Chief Information OfficerMar 10Option Exercise0.0020,8060152,400Mar 12 06:19 PM
Powell AnnEVP, Chief Human ResourcesMar 10Option Exercise0.0031,169058,421Mar 12 06:17 PM
Santiago Karen MurphyControllerMar 10Option Exercise0.005,06307,778Mar 12 06:17 PM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0051,5980588,175Mar 12 06:15 PM
Eid JosephSVP,Head Glob. Medical AffairsMar 10Option Exercise0.001,57106,652Mar 12 06:13 PM
Elicker John EEVP, Investor RelationsMar 10Option Exercise0.0018,407075,102Mar 12 06:14 PM
Caforio GiovanniChairman and CEOMar 10Option Exercise0.00211,7960544,032Mar 12 06:11 PM
Dubow AdamSVP,ChiefCompliance&EthicsOff.Mar 10Option Exercise0.005,007020,091Mar 12 06:12 PM
Bancroft Charles AEVP, Head of IntegrationMar 10Option Exercise0.0071,8680153,637Mar 12 06:11 PM
BOERNER CHRISTOPHER S.EVP, Chief Commercial OfficerMar 10Option Exercise0.0021,426026,091Mar 12 06:11 PM
Elicker John EEVP, Investor RelationsMar 04Sale61.0115,805964,26358,666Mar 06 05:20 PM
VESSEY RUPERTPres., Research & Early Dev.Mar 02Option Exercise51.6993,4684,831,452132,651Mar 04 06:19 PM
VESSEY RUPERTPres., Research & Early Dev.Mar 02Sale60.5984,3085,108,22248,343Mar 04 06:19 PM
AHMED NADIMPresident, HematologyMar 01Option Exercise0.0017,204033,028Mar 03 08:04 PM
Elkins David VEVP, Chief Financial OfficerMar 01Option Exercise0.0024,579044,766Mar 03 08:04 PM
VESSEY RUPERTPres., Research & Early Dev.Mar 01Option Exercise0.0023,349048,106Mar 03 08:05 PM